Clostridium Difficile Infection Treatment Market to Register CAGR 9% Rise in Growth by 2019 to 2029

The critical need for non-antibiotic alternatives for prophylaxis and treatment ofClostridium difficileinfections is shaping the market landscape ofClostridium difficileinfection treatment. The globalClostridium difficileinfection treatment market was valuedUS$ 840 Mnin 2018 and will exhibit a promising CAGR during the forecast period (2019 – 2029).

Key factors such as easy accessibility of diagnostic tests and accessibility of generic antimicrobial drugs (metronidazole and Vancomycin) continue to fuel theClostridium difficileinfection treatment market growth.

Get Sample Copy of Report @https://www.persistencemarketresearch.com/samples/15775

Company Profiles

• Merck & Co., Inc
• Baxter International Inc.
• Sanofi S.A.
• Pfizer Inc.
• Novartis AG
• Astellas Pharma
• Eli LilIy & Company
• AstraZeneca
• Actelion Pharmaceuticals Ltd (Sub. of Johnson & Johnson Services, Inc.)
• Mylan N.V.

Increasing incidence ofClostridium difficileinfection demands for strengthening R&D program, thereby propelling growth of theClostridium difficileinfection treatment market. In 2017, Actelion conducted phase III clinical trial for comparing cadazolid with vancomycin for the treatment ofClostridium difficileassociated diarrhea.

As per Center for Disease Control & Prevention (CDC) 2015, prevalence ofC. difficileinfection is increasing and is most common healthcare-associated infection among adults.

Key Takeaways –Clostridium difficileInfection Treatment Market Study

• Clostridium difficileinfection treatment market is characterized as mature market. Whereas, introduction of new class of therapeutic agents (such as monoclonal antibodies) for treatment is expected to generate market growth opportunities.
• Metronidazole, Fidaxomicin, and Vancomycin are most commonly prescribed medication. Although, prescription pattern is diverse across the world attributing to variation in the occurrence ofClostridium difficileinfection after treatment with each class of drug.
• In the U.S., metronidazole is suggested as a first line drug forClostridium difficiletreatment followed by the combination of vancomycin and fidaxomicin. In Western nations such as the U.S., Canada, and few European nations, utilization of anti-infection agents has flooded for over two decades, thus increasing the incidence ofClostridium difficileinfection in these regions.
• The sale of fidaxomicin, vancomycin, and metronidazole through retail pharmacies and mail order pharmacies is increasingly contributing to the globalClostridium difficiletreatment market growth.
• Uncontrolled utilization of broad range anti-infection drugs and absence of consistent cleanliness standards at clinics are increasing the rate of prevalence ofClostridium difficileinfection.

Get To Know Methodology of Report @https://www.persistencemarketresearch.com/methodology/15775

Launch of monoclonal antibody drugs for treatment ofClostridium difficileinfection and counteractive action for recurrentClostridium difficileinfection has shifted the focus from antibiotics to recently approved therapeutic class of drugs. This new class of drugs represents a breakthrough and will create an extreme challenge for conventional antibiotic medicines forClostridium difficileinfection.

Strategic Partnerships – Winning Imperatives for Market Leaders

The key players are focusing on new product launches, collaborations, territorial expansion, mergers, and acquisitions to increase share in the market. Mergers and acquisitions are helping these players to enhance existing product portfolio and topographical reach. For example, to fortify their pharmaceutical business, Johnson & Johnson acquired Actelion Ltd, enhancing the product portfolio forClostridium difficileinfection treatment.

To increase the market revenue, Astellas Pharma Inc. launched DafclirTablets 200 mg for the treatment of infectious enteritis (susceptible strains: fidaxomicin susceptibleClostridium difficile(CD)2) in Japan.To strengthen its product portfolio, USFDA granted acceptance for review of New Drug Application for DIFICID (fidaxomicin) for oral suspension in pediatric patients.

Access Full Report @https://www.persistencemarketresearch.com/checkout/15775

More Valuable Insights onClostridium difficileInfection Treatment Market

Persistence Market Research offers a unique perspective and actionable insights onClostridium difficileInfection treatment in its latest study, presenting historical demand assessment from 2014 – 2018 and projections from 2019 – 2029.

The globalClostridium difficileinfection treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

The study provides compelling insights onClostridium difficileinfection treatment market on basis of drug type (Metronidazole, Vancomycin, Fidaxomicin), route of administration (oral, injectable) and distribution channel (hospital pharmacies, retail pharmacies, mail order pharmacies) across five major regions.